Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy. [PDF]
, 2022 Study objectivesThis post hoc analysis characterized the weekly incidence and overall duration of common early-onset, treatment-emergent adverse events (TEAEs) during solriamfetol treatment.MethodsParticipants (obstructive sleep apnea [OSA], n = 474 ...
Bujanover, Shay +8 more
core +2 more sources
Narcolepsy Treatment: Present and Future [PDF]
, 2021 Narcolepsy is a chronic, disabling sleep disorder with a significant diagnostic delay. Nowadays, treatment is focused on managing symptoms that impacts patient’s life, such as at workplace, social events or even at school, but not aimed cure the disease.
Gabás, Patricia Ortega +6 more
core +2 more sources
Present and Future of Central Disorders of Hypersomnolence. [PDF]
J Sleep ResABSTRACT Central disorders of hypersomnolence (CDH) are rare neurological conditions lumped by excessive daytime sleepiness (EDS) as primary complaint mostly arising at young age, including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and Kleine‐Levin syndrome (KLS). Advances in clinical and translational research have
Biscarini F +4 more
europepmc +2 more sources
Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial [PDF]
, 2023 BackgroundNarcolepsy is a life-long disorder characterised by excessive daytime sleepiness and cataplexy, often arising in childhood or adolescence. Pitolisant, a selective histamine H3 receptor inverse agonist, has been approved in Europe and USA for ...
Caussé, C. +10 more
core +2 more sources
Novel Psychoactive Substances 14Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs [PDF]
, 2017 A feature of human culture is that we can learn to consume chemical compounds, derived from natural plants or synthetic fabrication, for their psychoactive effects.
Boris B. , Quednow +8 more
core +1 more source
Sleep Medicine and the Evolution of Contemporary Sleep Pharmacotherapy [PDF]
, 2022 Sleep is a fundamental physiological feature experienced by all known mammalian, and most non-mammalian, species. Underscoring its importance is the wide array of neural and cellular processes that have evolved to govern when and how it occurs, its ...
core +1 more source
Sleep disorders in Lewy body dementia: Mechanisms, clinical relevance, and unanswered questions
Alzheimer's &Dementia, Volume 19, Issue 11, Page 5264-5283, November 2023., 2023 Abstract In Lewy body dementia (LBD), disturbances of sleep and/or arousal including insomnia, excessive daytime sleepiness, rapid eye movement (REM) sleep behavior disorder, obstructive sleep apnea, and restless leg syndrome are common. These disorders can each exert a significant negative impact on both patient and caregiver quality of life; however,
Leigh T. J. Townsend +4 more
wiley +1 more source
Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial [PDF]
, 2012 Background: Fibromyalgia is characterised by chronic musculoskeletal pain and multiple symptoms including fatigue, multidimensional function impairment, sleep disturbance and tenderness.
Bennett, Robert M +5 more
core +2 more sources
Nocturnal Temazepam in the Treatment of Narcolepsy [PDF]
, 2013 Narcolepsy is characterized by fragmented nighttime sleep and frequent arousals. One treatment approach to improve daytime symptoms is to consolidate nighttime sleep through decreasing arousals.
Kansagra, Sujay +2 more
core +2 more sources
Assessing Ethnic Minority Representation in Fibromyalgia Clinical Trials: A Systematic Review of Recruitment Demographics [PDF]
, 2023 This is the final version. Available on open access from MDPI via the DOI in this recordData Availability Statement: Data used for analysis can be supplied from the corresponding author upon request.The under-representation of non-White participants in ...
Henley, P, Martins, T, Zamani, R
core +1 more source